Trial Identifier: | D9450C00001 |
Sponsor: | AstraZeneca |
Collaborator: |
ImaginAb, Inc.
|
NCTID:: | NCT05397171 |
Start Date: | June 2022 |
Primary Completion Date: | June 2023 |
Study Completion Date: | June 2023 |
Condition: | Lung Cancer; Colorectal Cancer; Bladder - Other |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
Language | Description |
English Version | |
English (Canada) Translation |
Country | Location |
---|---|
CA, ON | Ottawa, ON, CA, K1H 8L6 |
CA, Ontario | Toronto, Ontario, CA, M5G 1X5 |
ES | Barcelona, ES, 08035 |
ES | Barcelona, ES, 08036 |
ES | Madrid, ES, 28040 |
ES | Madrid, ES, 28050 |
ES | Madrid, ES, 28027 |
ES | Pamplona, ES, 31008 |
FR | Marseille, FR, 13015 |
FR | Toulouse Cedex 9, FR, 31059 |
FR | Villejuif Cedex, FR, 94805 |
GB | Cambridge, GB, CB2 0QQ |
GB | Glasgow, GB, G12 0YN |
GB | LONDON, GB, NW3 2QG |
GB | Newcastle Upon Tyne, GB, NE7 7DN |
US, CT | New Haven, CT, US, 06510 |
US, GA | Atlanta, GA, US, 30322 |
US, IA | Iowa City, IA, US, 52242 |
US, MI | Detroit, MI, US, 48201 |
US, MO | Saint Louis, MO, US, 63110 |
US, NV | Las Vegas, NV, US, 89169 |
US, RI | Providence, RI, US, 02903 |
US, WA | Seattle, WA, US, 98109 |